Biotech Values

[mcbio]

There's also a trial for a compound called 382 that doesn't ring a bell. Anyone remember what that is?
clinicaltrials.gov/ct2/show/NCT01316822

That's the cFMS inhibitor for oncology partnered with CELG (for which ARRY recently received $10M for the drug entering Phase 1).